The quad pill, a once-daily combination therapy for HIV infection

Clinical Infectious Diseases

Volumn 58, Issue 1, 2014, Pages 93-98

  Saravolatz, Louis D ^a   Johnson, Leonard B ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cobicistat; elvitegravir; emtricitabine; HIV; tenofovir

Indexed keywords

BILIRUBIN; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CREATININE; CYTOCHROME P450 3A; EMTRICITABINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; RALTEGRAVIR; TENOFOVIR; TENOFOVIR DIFUMARATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ANTIVIRAL RESISTANCE; CENTRAL NERVOUS SYSTEM DISEASE; CROSS RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; GENE MUTATION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KIDNEY TUBULE ABSORPTION; NAUSEA; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; HIV; TENOFOVIR;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; GLOMERULAR FILTRATION RATE; HIV; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; NAUSEA; TABLETS; TREATMENT OUTCOME;

EID: 84891364162     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit637     Document Type: Review

References (31)

1. U.S. Pharmaceutical Sales-Quarter 2, 2013. Available at: http://www. drugs.com/stats/top100/sales. Accessed 10 October 2013.
2. Edurant (rilpivirine) [package insert]. Raritan, NJ: Tibotec Therapeutics; 2011.
3. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilivirine versus efavirenz with two background nucleoside or nucleotide reverse transcripase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229-37.
4. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 2009; 48:931-9.
5. Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMARK. Clin Infect Dis 2011; 53:807-16.
6. De Castro Braun J, Charreau I, et al. Switch from enfurvitide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009; 49:1259-67.
7. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomized, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 12:907-15.
8. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment experienced patients. J Acquir Immune Defic Syndr 2006; 43:1-5.
9. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Therap 2010; 87:322-9.
10. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-table fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010; 55:323-9.
11. Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011; 50:229-44.
12. German P, Warren D, Wei L, et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF, and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet [abstract A1-1333]. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). 2009.
13. Stribild [package insert]. Foster City, CA: Gilead Sciences; 2012.
14. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-74.
15. Johnson VA, Calvez V, Hunthard H, et al. Update of the drug resistance mutations in HIV-1. Top Antiviral Med 2013; 21:6-14.
16. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antiviral Med 2013; 21:6-14.
17. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011; 25:1175-8.
18. Ceccherini-Silberstein F, Van Baelen K, Armenia D, et al. Secondary integrase inhibitor mutations found in HIV-1 minority quasispecies in integrase therapy-naïve patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Ag Chemother 2010; 54:3938-48.
19. Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54:389-93.
20. Molina JM, LaMarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatmentexperienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitors: randomized, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12:27-35.
21. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil-fumarate versus ritonavirboosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil-fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
22. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil-fumarate versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis after results of 48 weeks. Lancet 2012; 379:2439-48.
23. Zolopa AR, Berger DS, Lampiris H, et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201:814-22.
24. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25: F7-12.
25. Shannon JA. The renal excretion of creatinine in man. J Clin Invest 1935; 14:403-10.
26. Berglund F, Killander J, Pompeius R. Effect of trimethoprim- sulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114:802-8.
27. Burgess E, Blair A, Krichman K, et al. Inhibition of renal creatinine secretion by cimetidine in humans. Ren Physiol 1982; 5:27-30.
28. Lepist EI, Murray BP, Tong L, et al. Effect of cobicistat and ritonavir on proximal tubular cell uptake and efflux transporters [abstract A1-1724]. In: Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). 2011.
29. Cohen CJ, Andrade-Villanueva J, Clotet C, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomized, non-inferiority trial. Lancet 2011; 378:229-37.
30. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-8.
31. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012; 61:32-40.